1-(N-Boc)-1H-Pyrrole-2-Boronic Acid

When a Boc-Protected Pyrrole Enters a cGMP Suzuki Coupling

In the synthesis of active pharmaceutical intermediates destined for small-molecule kinase inhibitors, 1-(N-Boc)-1H-pyrrole-2-boronic acid serves as a masked pyrrole nucleophile that circumvents the handling difficulties associated with free 2-pyrroleboronic acid. A representative coupling employs the boronic acid at 1.0–1.3 equivalents with respect to a heteroaryl bromide such as a 4-chloropyrrolo[2,3-d]pyrimidine scaffold in a thermostatted, glass-lined stirred tank reactor purged with nitrogen to maintain an oxygen concentration below 50 ppm. The catalytic system is typically composed of PdCl₂(dppf) at 0.5–2 mol% or a combination of Pd(OAc)₂ at 0.5 mol% and triphenylphosphine-3,3′,3′′-trisulfonic acid trisodium salt (TPPTS) for improved aqueous solubility, suspended in a degassed mixture of tetrahydrofuran and 2 M aqueous sodium carbonate solution. Internal pH is continuously monitored via an InPro 3250i probe and maintained between 9.5 and 10.5 by controlled addition of sodium carbonate; pH excursions above 11 accelerate the partial cleavage of the N-Boc protecting group, liberating free pyrroleboronic acid which undergoes homo-coupling to form 1,2-bis(pyrrol-2-yl)-ethane-type dimers. Reaction temperatures are held below 80°C with a jacket-thermostat hysteresis of ±2°C, as differential scanning calorimetry data on similar N-Boc pyrroles indicates an exothermic onset of thermolytic deprotection near 105°C that can overwhelm plant-scale cooling capacity. Upon completion, typically within 4–8 hours monitored by in-process HPLC (Column: C18, 5 µm, detection at 254 nm), the crude mixture is treated with a mercaptopropyl-functionalized silica scavenger at 0.5–1.0 g per gram of theoretical palladium to reduce residual Pd below the 10 ppm threshold mandated by ICH Q3D guidelines for oral drug substances. The organic phase is concentrated under vacuum, and the crude solid crystallized from methyl tert-butyl ether/n-heptane to deliver the Boc-protected biaryl intermediate with a purity exceeding 99.5 area% by HPLC and a single largest unknown impurity below 0.10%. This intermediate is subsequently elaborated into APIs that fall under the scope of ICH Q7 GMP and are often required to meet monographs of the United States Pharmacopeia (e.g., USP <621> for chromatography and USP <231> for heavy metals, now superseded by elemental impurity limits). The entire process is validated for cleaning verification, requiring swab limits for the boron-containing species below 1 µg/cm² on product-contact surfaces, and the waste aqueous streams are monitored for boron content to comply with local discharge consents typically capped at 2 mg/L for boron.

The selection of catalyst is balanced against the cost of palladium metal and the stringency of genotoxic impurity control, as the Boc-deprotected pyrrole dimer is flagged under ICH M7 as a potential structural alert when its mass exceeds the threshold of toxicological concern of 1.5 µg/day in the final API.

Phenylpyrrole Fungicide Intermediate Synthesis and Phase-Transfer Catalysis

For technical-grade fludioxonil-related phenylpyrrole fungicides, manufacturing campaigns utilize this boronic acid at a slightly reduced excess of 1.02–1.08 equivalents to minimize boron-containing waste, coupled with 2,2-difluoro-1,3-benzodioxole-4-carbonitrile or its brominated analog in a biphasic toluene-water system. A typical 10,000 L enamel-lined reactor is charged with the aryl halide, tetrabutylammonium bromide at 5 mol% as phase-transfer catalyst, and palladium tetrakis(triphenylphosphine) at 0.5–1.0 mol% under a positive nitrogen pressure of 0.2–0.5 bar. The aqueous layer incorporates potassium carbonate at 2.0–2.3 equivalents in deionized water; during the heating ramp to reflux at 108–112°C, the reactor temperature is logged at 1 min intervals to ensure the N-Boc protective group survives the high-temperature regime — accelerated stability data indicates that 5–8% of the Boc group can be lost over 24 h at 110°C in the presence of 2.5 eq K₂CO₃, producing free pyrrole that can form intractable tars via oxidative polymerization. To mitigate this, the reaction is quenched once in-process HPLC shows the aryl halide content below 0.5 area%, typically achieved in 3–5 hours. The organic layer is separated at 70–80°C to avoid precipitation, washed with 5% aqueous sodium bisulfite to complex residual palladium, and passed through a 0.5 µm sparkler filter pre-coated with activated carbon. After vacuum distillation of the solvent, the crude solid is recrystallized from a cyclohexane/ethyl acetate mixture (9:1 v/v) to afford the intermediate as off-white crystals with a melt point of 142–144°C and purity ≥98.5% (HPLC, λ=280 nm). This intermediate is then deprotected under acidic conditions with trifluoroacetic acid in dichloromethane at 0–5°C and elaborated to the active ingredient in subsequent steps. Compliance with the FAO specifications for the technical material includes a certified loss on drying below 0.5%, water content by Karl Fischer titration below 0.3%, and a limit of 5 mg/kg for any individual unspecified impurity. The entire chain from intermediate to final product is operated under an ISO 9001:2015 quality management system, and the analytical release testing is carried out according to ISO 17025-accredited methods. Wastewater emerging from the aqueous phase after the Suzuki step is treated with dithiocarbamate-based metal precipitants to bring total palladium below the local sewer discharge limit of 0.1 mg/L.

What Level of Residual Palladium Disqualifies an Electronic-Grade Polymer?

When this boronic acid is employed as a co-monomer for light-emitting or hole-transporting conjugated polymers, the synthesis shifts from a fine-chemical paradigm to an electronic-materials protocol in which metallic contamination exerts a disproportionate influence on device efficiency and lifetime. In the preparation of a poly(2,5-di-n-octylphenylene-1,4-alt-pyrrole-2,5-diyl) copolymer, exact 1:1 stoichiometry of the Boc-protected pyrrole diboronic acid equivalent is prescribed—given that 1-(N-Boc)-1H-pyrrole-2-boronic acid is a monofunctional building block, it is typically employed to cap a growing chain or to construct a discrete small molecule that is then polymerized. In the context of a donor–acceptor polymer, a brominated benzothiadiazole monomer is first end-capped with this pyrrole boronic acid using Pd₂(dba)₃ at 0.5 mol% and 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (SPhos) at 1.2 mol% in a mixed anhydrous toluene/ethanol system at 85°C for 12 h. The crude adduct is sequentially washed with a 5% aqueous sodium diethyldithiocarbamate solution, passed through a column of Thiol-Modified Silica Gel (particle size 40–63 µm), and precipitated into methanol. The dried intermediate must exhibit a residual Pd content below 5 ppm and a boron content below 15 ppm as determined by inductively coupled plasma mass spectrometry (ICP-MS) before proceeding to polymerization. When the material fails these limits, device performance in a single-carrier device configuration drops sharply: a hole mobility measured by space-charge-limited current (SCLC) falls from 10⁻⁴ cm²/V·s to below 10⁻⁶ cm²/V·s in the presence of 20 ppm Pd. The final assembled polymer is dissolved in anhydrous chlorobenzene and spin-coated inside a nitrogen-filled glovebox with O₂ and H₂O levels each below 0.1 ppm. The entire material lifecycle from raw boronic acid to final polymer solution is governed by a supplier–customer quality agreement that references SEMI C43-0723 standards for organic electronic materials and often includes an out-of-specification protocol requiring root-cause analysis when any batch exceeds 10 ppm of total transition metals. End-use devices incorporating these polymers are typically organic light-emitting diodes or organic photovoltaic cells fabricated on ITO-coated glass substrates, where the pyrrole unit functions to raise the HOMO level, tuning the hole injection barrier by approximately 0.3–0.5 eV.

Parallel synthesis workflows in drug discovery routinely employ this building block at 1.2 eq with Pd(dppf)Cl₂·CH₂Cl₂ at 2 mol% in dioxane/water mixtures at 80°C to generate biaryl libraries for kinase screening; the crude reaction mixtures are filtered through silica plugs and submitted for biological evaluation without extensive purification, conforming to institutional chemical safety and waste disposal protocols rather than pharmacopoeial monographs.

In the total synthesis of marine pentacyclic alkaloids of the lamellarin class, which exhibit selective cytotoxicity against multi-drug-resistant cancer cell lines, the introduction of the pyrrole-2-carboxylate unit via Suzuki coupling has been reported using this N-Boc-protected boronic acid. On a laboratory scale of 5–50 g, the boronic acid at 1.5–2.0 eq is combined with an iodinated isoquinolinecarboxylate in a sealed microwave vessel containing Pd(PPh₃)₄ at 5–10 mol% and cesium carbonate at 3 eq in a solvent mixture of 1,2-dimethoxyethane/water (3:1 v/v). The mixture is irradiated at 130°C for 30–45 min in a monomode microwave reactor with a maximum power setting of 300 W, maintaining an internal pressure that stays below 15 bar. After cooling, the pH is adjusted to 6–7 with dilute hydrochloric acid to precipitate the free carboxylic acid intermediate, which is collected, washed, and dried. This intermediate is then deprotected with neat formic acid at 40°C to remove the Boc group, liberating the pyrrole NH for subsequent carbon–nitrogen bond formation in the construction of the lamellarin skeleton. Given the research-stage nature of this work, the process is performed according to institutional good laboratory practice (GLP) guidelines, with all waste streams categorized and disposed as halogenated solvent waste; no specific pharmacopoeial monograph applies. The end product is a lamellarin analogue, typically isolated as a trifluoroacetate salt after preparative reverse-phase HPLC, and is employed exclusively as a biological probe in tubulin polymerization assays and apoptosis studies, not as a commercial therapeutic agent. Trace analysis of the final compound by ICP-MS shows residual palladium consistently below 25 ppm, which is acceptable for in vitro screening at test concentrations below 10 µM.